1
|
Zazo H, Colino CI, Gutiérrez-Millán C, Cordero AA, Bartneck M, Lanao JM. Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution. Pharmaceutics 2022; 14:pharmaceutics14020406. [PMID: 35214138 PMCID: PMC8875329 DOI: 10.3390/pharmaceutics14020406] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 02/10/2022] [Accepted: 02/11/2022] [Indexed: 11/16/2022] Open
Abstract
Computational modelling has gained attention for evaluating nanoparticle-based drug delivery systems. Physiologically based pharmacokinetic (PBPK) modelling provides a mechanistic approach for evaluating drug biodistribution. The aim of this work is to develop a specific PBPK model to simulate stavudine biodistribution after the administration of a 40 nm gold nanoparticle-based drug delivery system in rats. The model parameters used have been obtained from literature, in vitro and in vivo studies, and computer optimization. Based on these, the PBPK model was built, and the compartments included were considered as permeability rate-limited tissues. In comparison with stavudine solution, a higher biodistribution of stavudine into HIV reservoirs and the modification of pharmacokinetic parameters such as the mean residence time (MRT) have been observed. These changes are particularly noteworthy in the liver, which presents a higher partition coefficient (from 0.27 to 0.55) and higher MRT (from 1.28 to 5.67 h). Simulated stavudine concentrations successfully describe these changes in the in vivo study results. The average fold error of predicted concentrations after the administration of stavudine-gold nanoparticles was within the 0.5–2-fold error in all of the tissues. Thus, this PBPK model approach may help with the pre-clinical extrapolation to other administration routes or the species of stavudine gold nanoparticles.
Collapse
Affiliation(s)
- Hinojal Zazo
- Area of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain; (H.Z.); (C.G.-M.); (A.A.C.)
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
| | - Clara I. Colino
- Area of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain; (H.Z.); (C.G.-M.); (A.A.C.)
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
- Correspondence: (C.I.C.); (J.M.L.); Tel.: +34-923-294-536 (C.I.C.)
| | - Carmen Gutiérrez-Millán
- Area of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain; (H.Z.); (C.G.-M.); (A.A.C.)
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
| | - Andres A. Cordero
- Area of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain; (H.Z.); (C.G.-M.); (A.A.C.)
| | - Matthias Bartneck
- Department of Medicine III, Medical Faculty, RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Germany;
| | - José M. Lanao
- Area of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Avda Lcdo Méndez Nieto, 37007 Salamanca, Spain; (H.Z.); (C.G.-M.); (A.A.C.)
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
- Correspondence: (C.I.C.); (J.M.L.); Tel.: +34-923-294-536 (C.I.C.)
| |
Collapse
|
2
|
Casanova AG, Prieto M, Colino CI, Gutiérrez-Millán C, Ruszkowska-Ciastek B, de Paz E, Martín Á, Morales AI, López-Hernández FJ. A Micellar Formulation of Quercetin Prevents Cisplatin Nephrotoxicity. Int J Mol Sci 2021; 22:E729. [PMID: 33450917 PMCID: PMC7828436 DOI: 10.3390/ijms22020729] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 01/10/2021] [Accepted: 01/11/2021] [Indexed: 12/18/2022] Open
Abstract
The antioxidant flavonoid quercetin has been shown to prevent nephrotoxicity in animal models and in a clinical study and is thus a very promising prophylactic candidate under development. Quercetin solubility is very low, which handicaps clinical application. The aim of this work was to study, in rats, the bioavailability and nephroprotective efficacy of a micellar formulation of Pluronic F127-encapsulated quercetin (P-quercetin), with improved hydrosolubility. Intraperitoneal administration of P-quercetin leads to an increased plasma concentration and bioavailability of quercetin compared to the equimolar administration of natural quercetin. Moreover, P-quercetin retains overall nephroprotective properties, and even slightly improves some renal function parameters, when compared to natural quercetin. Specifically, P-quercetin reduced the increment in plasma creatinine (from 3.4 ± 0.5 to 1.2 ± 0.3 mg/dL) and urea (from 490.9 ± 43.8 to 184.1 ± 50.1 mg/dL) and the decrease in creatinine clearance (from 0.08 ± 0.02 to 0.58 ± 0.19 mL/min) induced by the nephrotoxic chemotherapeutic drug cisplatin, and it ameliorated histological evidence of tubular damage. This new formulation with enhanced kinetic and biopharmaceutical properties will allow for further exploration of quercetin as a candidate nephroprotector at lower dosages and by administration routes oriented towards its clinical use.
Collapse
Affiliation(s)
- Alfredo G. Casanova
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (A.G.C.); (M.P.); (C.I.C.); (C.G.-M.)
- Department of Physiology and Pharmacology, University of Salamanca, 37007 Salamanca, Spain
- Toxicology Unit, University of Salamanca, 37007 Salamanca, Spain
| | - Marta Prieto
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (A.G.C.); (M.P.); (C.I.C.); (C.G.-M.)
- Department of Physiology and Pharmacology, University of Salamanca, 37007 Salamanca, Spain
- Toxicology Unit, University of Salamanca, 37007 Salamanca, Spain
| | - Clara I. Colino
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (A.G.C.); (M.P.); (C.I.C.); (C.G.-M.)
- Area of Pharmacy and Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Salamanca, 37007 Salamanca, Spain
| | - Carmen Gutiérrez-Millán
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (A.G.C.); (M.P.); (C.I.C.); (C.G.-M.)
- Area of Pharmacy and Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Salamanca, 37007 Salamanca, Spain
| | - Barbara Ruszkowska-Ciastek
- Department of Pathophysiology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, 85-796 Bydgoszcz, Poland;
| | - Esther de Paz
- High Pressure Processes Group, BioEcoUVa, Bioeconomy Research Institute, Department of Chemical Engineering and Environmental Technology, University of Valladolid, 47011 Valladolid, Spain; (E.d.P.); (Á.M.)
| | - Ángel Martín
- High Pressure Processes Group, BioEcoUVa, Bioeconomy Research Institute, Department of Chemical Engineering and Environmental Technology, University of Valladolid, 47011 Valladolid, Spain; (E.d.P.); (Á.M.)
| | - Ana I. Morales
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (A.G.C.); (M.P.); (C.I.C.); (C.G.-M.)
- Department of Physiology and Pharmacology, University of Salamanca, 37007 Salamanca, Spain
- Toxicology Unit, University of Salamanca, 37007 Salamanca, Spain
| | - Francisco J. López-Hernández
- Institute of Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain; (A.G.C.); (M.P.); (C.I.C.); (C.G.-M.)
- Department of Physiology and Pharmacology, University of Salamanca, 37007 Salamanca, Spain
| |
Collapse
|
3
|
Affiliation(s)
- José M. Lanao
- Area of Pharmacy and Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Salamanca, 37007 Salamanca, Spain; (J.M.L.); (C.I.C.)
- The Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
| | - Carmen Gutiérrez-Millán
- Area of Pharmacy and Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Salamanca, 37007 Salamanca, Spain; (J.M.L.); (C.I.C.)
- The Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
- Correspondence:
| | - Clara I. Colino
- Area of Pharmacy and Pharmaceutical Technology, Department of Pharmaceutical Sciences, University of Salamanca, 37007 Salamanca, Spain; (J.M.L.); (C.I.C.)
- The Institute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain
| |
Collapse
|